Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.32 EUR | -0.90% | -5.14% | -18.93% |
Mar. 28 | Transcript : Inventiva S.A., 2023 Earnings Call, Mar 28, 2024 | |
Mar. 27 | Inventiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.93% | 187M | - | ||
+2.73% | 108B | B+ | ||
+9.59% | 103B | B+ | ||
+6.58% | 23.48B | B | ||
-12.59% | 21.93B | B+ | ||
-3.29% | 19.68B | A- | ||
-35.36% | 18.37B | A- | ||
-13.29% | 16.33B | B | ||
+4.68% | 13.72B | C+ | ||
+34.25% | 12.15B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Inventiva - Euronext Paris
- Ratings Inventiva